For most of its life, Travere was a small rare-disease company running hard to stay ahead of its own losses. Revenue was thin, the pipeline was speculative, and the net margin, the share of each sales dollar left after every cost, sat deep in the red every single year. Then one drug changed the arithmetic. The question now is whether the filed numbers justify a stock that has more than doubled in twelve months.
What matters here
The filed numbers show a business that went from burning through most of its revenue to nearly breaking even in a single year. The stock, meanwhile, is priced at roughly ten times annual sales, a level that assumes the growth keeps compounding. The open question is whether a second FDA approval, granted in April 2026, can sustain the pace, or whether the market has already priced in the good news.
A tale of two numbers that should not coexist
Consider this: full-year 2025 revenue of $491 million, more than double the prior year, sitting alongside a net margin that is barely negative. A company growing that fast while still losing money is not unusual in biotech. What is unusual is how close to zero that loss figure sits. For years, Travere was spending well over a dollar for every dollar it brought in. By the end of 2025, the gap had nearly closed. That shift happened faster than almost any comparable turn in the company’s own history.
The engine behind that shift is FILSPARI, the brand name for sparsentan, a drug first approved for IgA nephropathy, a rare kidney disease. Then, on April 13, 2026, the FDA approved FILSPARI for a second kidney disease, focal segmental glomerulosclerosis, or FSGS. That second label opened a new patient population overnight.
What the most recent quarter shows
The 10-Q for the quarter ended June 30, 2026 is the freshest filed evidence. FILSPARI generated $141.1 million in U.S. net product sales in that single quarter, a near-doubling from the same period a year earlier, according to the Q2 2026 press release. To put that in human terms: the drug is now earning in three months nearly as much as the entire company earned in a full year as recently as 2023 ($145 million). The Thiola franchise, two older drugs for a rare metabolic condition called cystinuria, added a further increment, bringing total U.S. product sales to $161.4 million for the quarter.
The more than two thousand new patient start forms filed in Q2 matter as a leading signal. A patient start form is the paperwork a doctor submits when beginning a patient on a drug. More forms today means more revenue in coming quarters, assuming patients stay on therapy. That number is what the math watches closely.
The history that explains the present
Travere spent years absorbing losses to build the clinical evidence for sparsentan. The 2023 10-K shows revenue falling to $145 million as the company shed older assets and leaned entirely into its kidney franchise. That was the trough. The 2024 10-K shows revenue recovering to $233 million as FILSPARI’s first indication gained traction. The 2025 leap to $491 million reflects a full year of commercial momentum, plus the anticipation of the FSGS label that arrived in April 2026. The company also disclosed in its February 2026 full-year results that enrollment had resumed for the Phase 3 HARMONY study of pegtibatinase, a separate drug for a rare metabolic disorder called classical homocystinuria. That program is still early, and the data cannot yet say what it is worth.
The math and the mood
“The math” is what the filed fundamentals describe: a business that has nearly reached breakeven on a revenue base growing faster than almost any comparable rare-disease company. “The mood” is what the market is currently paying: our data puts the price-to-sales multiple, the price tag per dollar of annual revenue, at 10.0 times, modestly above the company’s own historical median. The stock has roughly doubled over the past twelve months, and sits meaningfully below its 52-week high, meaning some of the enthusiasm has already cooled.
The tension is straightforward. The filed numbers show a company that has genuinely transformed. The current price assumes that transformation continues at pace. A second kidney indication is real and filed. Whether it compounds into the kind of durable revenue stream that justifies a double-digit sales multiple is the question the next several quarters will answer, and the data does not yet have enough quarters to settle it.
Reading the numbers
$491 million, FY2025 revenue. This is the total money Travere collected from selling its drugs in 2025, per the 2025 10-K. It means the company more than doubled in size in a single year. Think of a shop that took in $230,000 one year and $491,000 the next: the shelves are the same, but one product suddenly started selling to twice as many customers.
Negative 5.2%, net margin, FY2025. For every dollar of revenue, the company spent $1.05. That sounds bad, but compare it to negative 137.9% in 2024, when it spent $2.38 for every dollar earned. The loss is nearly gone. A household that was spending $2,380 for every $1,000 it earned, and then cut that to $1,050, has not fixed its finances yet, but the direction is unmistakable.
$141.1 million, FILSPARI Q2 2026 sales. This is one drug’s revenue in one quarter, per the Q2 2026 10-Q. Annualized, it implies a run rate approaching $560 million from FILSPARI alone, before accounting for the FSGS label’s ramp. That single figure is doing most of the work in the investment case.
10.0 times price-to-sales. This is the price the market charges per dollar of annual revenue, per our data. The company’s own historical median is 9.3 times. Paying 10 times sales is not extreme for a rare-disease company with a growing franchise, but it leaves little room for a stumble in patient uptake or a pricing surprise from payers.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-Q for quarter ended March 31, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Travere Q2 2026 Financial Results press release
- Travere Q4 and Full-Year 2025 Financial Results press release
